Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
Nuvation Bio reported updated Phase 2 data for safusidenib in IDH1-mutant glioma, showing a 51.9% confirmed objective response rate and a 79.1% progression-free survival rate at 36 months. Supported by these durable efficacy results, the company is expanding the program with a pivotal Phase 3 study (G307) for newly diagnosed patients outside the U.S. and a Phase 2 study (G209) for U.S. patients who progressed on vorasidenib.
Key figures
- Drug Name
- Safusidenib
- Phase Of Trial
- Phase 2
- Orr
- 51.9%
- Pfs 36 month rate
- 79.1%
- Patients phase2 g209
- 40
- Patients phase2 j201
- 27
- Patients phase3 g307
- 140
- Median follow up months
- 38.8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.